NEW
YORK, March 29, 2024 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders
of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
Shareholders who purchased shares of AMLX during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/amylyx-loss-submission-form/?id=73176&from=4
CLASS PERIOD: November 11,
2022 to November 8, 2023
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (i)
defendants had overstated commercial prospects RELYVRIO, a dual
UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and
taurursodiol for the treatment of ALS in adults in the U.S.; (ii)
patients were discontinuing treatment with RELYVRIO after six
months; (iii) the rate at which new patients were starting
treatment with RELYVRIO was decreasing; (iv) accordingly,
defendants had also overstated RELYVRIO's prescription rate; (v)
defendants attempted to hide the foregoing negative trends from
investors and the market by blocking analysts from viewing
RELYVRIO's prescription data; and (vi) as a result, defendants'
public statements were materially false and misleading at all
relevant times.
DEADLINE: April 9, 2024
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/amylyx-loss-submission-form/?id=73176&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of AMLX during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is April 9, 2024. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-amylyx-pharmaceuticals-incamlx-shareholders-302103011.html
SOURCE The Gross Law Firm